Before a single symptom stirs, a vial of blood may soon carry the knowledge of twelve cancers — a quiet revolution in how humanity confronts one of its oldest adversaries. The UK government has committed £2.5 million to bring the miONCO test, developed at Southampton University, closer to NHS deployment within five to seven years. Born from the clinical data of 20,000 patients and claiming 99 percent accuracy, the test represents a rare convergence of scientific ambition and public health will. It is a reminder that the most consequential battles are often won not at the bedside, but in the ye
NHS to fund 'game-changing' blood test detecting 12 cancers before symptoms
Just a couple of drops of blood could tell you if you had cancer
Mark
So this is a blood test that can find twelve different cancers before you have any symptoms. That's the core claim?
Mimi
Yes. They're saying it's 99 percent accurate and produces one false positive for every fifty real cancers it catches. That's genuinely rare in screening.
Luke
But we should be careful here. That 99 percent figure and the fifty-to-one ratio—those come from early trials, not from a large-scale population study. We don't yet know how it performs in the real world.
Mark
What makes this different from cancer screening we already have?
Mimi
Current NHS screening is fragmented. You get screened for breast cancer one way, bowel cancer another way. This single blood test would theoretically catch twelve cancers in one go. And it's looking for cancer before symptoms, which is the whole point of screening.
Luke
Right, but we only screen for four cancers right now—breast, bowel, cervical, and lung. There's a reason we don't screen for, say, pancreatic cancer in everyone. We'd need to know this test actually improves survival, not just that it detects cancer earlier.
Mark
When would people actually be able to use this?
Mimi
Five to seven years if everything goes according to plan. The government is funding £2.5 million to speed up development, particularly to make sure the AI works equally well for people from different ethnic backgrounds.
Luke
That's important, actually. The fact that they're explicitly testing on diverse populations suggests they know early versions might have blind spots. That's good practice, but it also means the test isn't ready yet.
Mark
What's the cost?
Mimi
£120 per test. That's not trivial, but it's less than what the NHS currently spends investigating false positives from existing screening.
Luke
Though we don't know yet what the false positive rate will be when this is used on millions of people rather than thousands in a trial. That's the real test.
O Pulso
- Twelve of the deadliest cancers — including lung, pancreatic, and brain — could be detected before a single symptom appears, upending the current reality where most diagnoses arrive too late.
- The existing NHS screening system covers only four cancer types, costs £800 million annually, and generates £91 million in false-alarm investigations — a system straining under its own limitations.
- The miONCO test claims to flag fifty true cancers before producing one false positive, a precision that would dramatically reduce the anxiety, cost, and delay of current diagnostic pathways.
- A £2.5 million government investment will fund AI refinement and trials across 8,000 blood samples from diverse ethnic backgrounds, ensuring the test does not perform unequally across populations.
- NHS rollout remains five to seven years away — a measured timeline that holds both the weight of genuine promise and the humbling reminder that breakthrough science must still pass through slow, necessary systems.
Before a single symptom stirs, a vial of blood may soon carry the knowledge of twelve cancers — a quiet revolution in how humanity confronts one of its oldest adversaries. The UK government has committed £2.5 million to bring the miONCO test, developed at Southampton University, closer to NHS deployment within five to seven years. Born from the clinical data of 20,000 patients and claiming 99 percent accuracy, the test represents a rare convergence of scientific ambition and public health will. It is a reminder that the most consequential battles are often won not at the bedside, but in the years of careful preparation that precede the moment of need.
A single vial of blood could soon reveal whether cancer is present — before any symptom has made itself known. The UK government has pledged £2.5 million to develop the miONCO test, created by Southampton University researchers using data from 20,000 cancer patients, with NHS availability projected within five to seven years.
The test screens for twelve cancers — among them lung, breast, prostate, pancreatic, and brain — and its developers report 99 percent accuracy, identifying fifty cancers before generating a single false positive. That precision stands in sharp contrast to the current NHS landscape, where screening exists for only four cancer types, costs £800 million annually, and produces £91 million in false-alarm follow-ups.
Health Secretary Wes Streeting, a cancer survivor himself, has championed the initiative as potentially game-changing — capable of eliminating the months patients currently wait for scans and biopsies. Professor Paul Skipp, who leads the Southampton research team, believes the test could save many thousands of lives each year by catching cancers far earlier than is currently possible. A startup, Xgenera, has been established to commercialize the £120-per-screening test.
The next phase will test the AI analysis system on 8,000 blood samples drawn from people of diverse ethnic backgrounds, a deliberate step to ensure equitable accuracy across populations. The timeline is unhurried by necessity — five to seven years of refinement stand between today's promise and the moment a patient might receive this test on the NHS. It is a long road, but the destination, if reached, could quietly transform the odds for tens of thousands of lives each year.
A single vial of blood could soon tell you whether you have cancer—before you feel a thing. The UK government has committed £2.5 million to develop and refine a blood test that detects twelve of the most common and lethal cancers at their earliest stages, potentially reshaping how the disease is caught and treated across the country.
The test, called miONCO, was developed by researchers at Southampton University using clinical data from 20,000 cancer patients. It screens for lung, breast, prostate, pancreatic, colorectal, ovarian, liver, brain, oesophageal, bladder, bone and soft tissue sarcoma, and gastric cancer. The developers claim it achieves 99 percent accuracy and identifies fifty cancers before producing a single false positive—a dramatic improvement over existing screening methods. Early trials suggest it can detect cancer at any stage, including before symptoms emerge.
Health Secretary Wes Streeting, himself a cancer survivor who lost a kidney during treatment, has framed the initiative as central to his mission in office. He described the test as potentially "game-changing," capable of eliminating the months-long waits patients currently endure for scans and biopsies. The current NHS screening landscape is narrow: only three cancer types—breast, bowel, cervical, and lung—have dedicated screening programs, and those rely on scans or biopsies that carry high rates of false positives. The NHS spends £800 million annually screening for these four cancers, with an additional £91 million spent investigating false alarms that turn out to be nothing.
Professor Paul Skipp of Southampton University, who leads the research team, said a test of this kind could "save many lives, catching cancers much earlier." The researchers have established a startup company called Xgenera to commercialize the test, which costs £120 per screening. They project NHS availability within five to seven years, contingent on further refinement of the artificial intelligence that analyzes blood samples and biomarkers.
The next phase of development will involve testing the AI system on 8,000 blood samples drawn from people of diverse ethnic backgrounds—a deliberate effort to ensure the test performs equally well across different populations. Streeting emphasized that Britain possesses two advantages in this race: world-leading scientific talent and an NHS with substantial untapped potential. He positioned the investment as both a health imperative and an economic opportunity, framing early cancer detection as part of a broader transformation in British medical science.
Skipp noted that a screening tool with genuinely low false positive rates would fundamentally reshape cancer detection procedures across the health service. The stakes are substantial: tens of thousands of lives could be saved annually if the test performs as developers claim. Yet the timeline is measured. Five to seven years of additional work separates current promise from actual NHS deployment—a reminder that even breakthrough science moves slowly through the systems that must ultimately deliver it to patients.
Citações Notáveis
A test like this could save many lives, catching cancers much earlier. We hope to have an NHS test in five to seven years.— Professor Paul Skipp, Southampton University
The earlier it is diagnosed, the better chance patients have of survival. It is my mission as Health Secretary that it is caught earlier and more are saved.— Health Secretary Wes Streeting
Quer a matéria completa?
Leia o original em Birmingham Live ↗
Health & Medicine